George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of Axim Biotechnologies, Inc. (OTCQB: AXIM), called in to SmallCapVoice.com to discuss the company’s business model, target markets and exciting recent news. The Company recently announced that it filed an IP application with the World Intellectual Property Organization (WIPO) on a proprietary method to extract THC-A (tetrahydrocannabinol acid) from cannabis plants and to achieve THC (tetrahydrocannabinol) with higher purity than conventional methods.
This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.